NASDAQ:APLSApellis Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apellis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $27.72 +2.21 (+8.66 %) (As of 04/8/2020 04:00 PM ET) Add Compare Share Today's Range$25.40Now: $27.72▼$27.8150-Day Range$17.91MA: $29.80▼$40.5652-Week Range$16.85Now: $27.72▼$45.04Volume940,394 shsAverage Volume1.47 million shsMarket Capitalization$2.09 billionP/E RatioN/ADividend YieldN/ABeta1.2 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for intravenous administration in systemic indications. It has a risk-sharing collaboration agreement with SFJ Pharmaceuticals Group for the development of APL-2 in hematologic indications. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingApellis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.00, Apellis Pharmaceuticals has a potential upside of 87.6% from its current price of $27.72.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesApellis Pharmaceuticals has received 200 “outperform” votes. (Add your “outperform” vote.)Underperform VotesApellis Pharmaceuticals has received 178 “underperform” votes. (Add your “underperform” vote.)Community SentimentApellis Pharmaceuticals has received 52.91% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote “Outperform” if you believe APLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.60% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions58.77% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow by 0.55% in the coming year, from ($5.48) to ($5.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 60.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLS Previous Symbol CUSIPN/A CIK1492422 Webhttp://www.apellis.com/ Phone617-977-5700Debt Debt-to-Equity Ratio4.51 Current Ratio5.67 Quick Ratio5.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book60.26Profitability EPS (Most Recent Fiscal Year)($4.64) Net Income$-304,710,000.00 Net MarginsN/A Return on Equity-208.64% Return on Assets-78.05%Miscellaneous Employees87 Outstanding Shares75,321,000Market Cap$2.09 billion Next Earnings Date5/13/2020 (Estimated) OptionableNot Optionable Receive APLS News and Ratings via Email Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:APLS Rates by TradingView Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions How has Apellis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APLS shares have increased by 1.8% and is now trading at $27.72. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Apellis Pharmaceuticals? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 3 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Apellis Pharmaceuticals. When is Apellis Pharmaceuticals' next earnings date? Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Apellis Pharmaceuticals. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals Inc (NASDAQ:APLS) posted its quarterly earnings results on Thursday, February, 27th. The company reported ($1.77) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.14) by $0.63. View Apellis Pharmaceuticals' earnings history. What price target have analysts set for APLS? 11 Wall Street analysts have issued 12 month target prices for Apellis Pharmaceuticals' stock. Their forecasts range from $29.00 to $86.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $52.00 in the next twelve months. This suggests a possible upside of 87.6% from the stock's current price. View analysts' price targets for Apellis Pharmaceuticals. Has Apellis Pharmaceuticals been receiving favorable news coverage? Headlines about APLS stock have trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Apellis Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutApellis Pharmaceuticals. Are investors shorting Apellis Pharmaceuticals? Apellis Pharmaceuticals saw a decline in short interest in March. As of March 13th, there was short interest totaling 5,825,200 shares, a decline of 9.5% from the February 27th total of 6,440,000 shares. Based on an average trading volume of 1,036,000 shares, the short-interest ratio is currently 5.6 days. Currently, 18.3% of the shares of the company are sold short. View Apellis Pharmaceuticals' Current Options Chain. Who are some of Apellis Pharmaceuticals' key competitors? Some companies that are related to Apellis Pharmaceuticals include Dr.Reddy's Laboratories (RDY), Mylan (MYL), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY) and Nektar Therapeutics (NKTR). What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), KemPharm (KMPH), Aurinia Pharmaceuticals (AUPH), Anavex Life Sciences (AVXL), Progenics Pharmaceuticals (PGNX), Arbutus Biopharma (ABUS) and Axsome Therapeutics (AXSM). Who are Apellis Pharmaceuticals' key executives? Apellis Pharmaceuticals' management team includes the following people: Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 47)Dr. Pascal Deschatelets, Co-Founder & COO (Age 49)Mr. Timothy E. Sullivan, Chief Financial Officer (Age 48)Dr. Federico Grossi M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Medical Affairs (Age 45)Mr. Ahmad Sadr, VP of Technical Operations When did Apellis Pharmaceuticals IPO? (APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO. What is Apellis Pharmaceuticals' stock symbol? Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS." How do I buy shares of Apellis Pharmaceuticals? Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Apellis Pharmaceuticals' stock price today? One share of APLS stock can currently be purchased for approximately $27.72. How big of a company is Apellis Pharmaceuticals? Apellis Pharmaceuticals has a market capitalization of $2.09 billion. The company earns $-304,710,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe. View additional information about Apellis Pharmaceuticals. What is Apellis Pharmaceuticals' official website? The official website for Apellis Pharmaceuticals is http://www.apellis.com/. How can I contact Apellis Pharmaceuticals? Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-977-5700 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Diversification For Individual Investors
